OncoTherapy Science, Inc.
OncoTherapy Science, Inc. (JPX: 4564) is trading at ¥21.00, about ₹13 at today's JPY/INR rate, as of 25 Sep 2026, 2:30 AM ET. Indian residents can buy OncoTherapy Science from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
¥21.00
Today's high
¥22.00
52 week low
¥18.00
52 week high
¥34.00
4564 opened at ¥21.00, closed previously at ¥21.00, and has traded between ¥18.00 and ¥34.00 over the past 52 weeks.
About
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Key statistics
Avg. volume
175.09M
Market cap
¥8.37B
P/E Ratio
-8.90
Price-to-sales ratio
10.76
Enterprise value
¥6.05B
Free cash flow yield
0.00%
Debt-to-equity ratio
0.00
Return on equity
-42.79%
ROIC
-34.53%
Beta
0.29
Dividend yield
0.00%
Last dividend
¥0.00
Financial overview
Revenue
¥808.53M
Earnings per share
-¥2.77
Free cash flow
-¥984.97M
Net profit margin
-113.81%
Gross margin
2.19%
EBITDA
-¥810.38M
Revenue growth
7.80%
Similar securities
This is not an investment recommendation
How to buy OncoTherapy Science from India
Indian residents can buy OncoTherapy Science shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.
Search for OncoTherapy Science and place an order
Find OncoTherapy Science by name or by its ticker, 4564, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. OncoTherapy Science trades 5:30 am – 12:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your OncoTherapy Science position in JPY and INR. OncoTherapy Science pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in OncoTherapy Science from India
Trading and taxes when buying OncoTherapy Science from India
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm JST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneOncoTherapy Science does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Estate or inheritance tax
- May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy OncoTherapy Science stock?
Yes. OncoTherapy Science (4564) has been listed on the Tokyo Stock Exchange since 2005, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one OncoTherapy Science share cost in rupees?
One OncoTherapy Science share is ¥21.00 — about ₹13 at a JPY/INR rate of 0.6090 on 26 Sep 2026. Both the OncoTherapy Science price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying OncoTherapy Science from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of OncoTherapy Science?
The Tokyo Stock Exchange typically trades in units of 100 shares.
How are gains on OncoTherapy Science shares taxed in India?
Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the OncoTherapy Science price. Paasa issues a capital-gains statement for your return.
Does OncoTherapy Science pay a dividend?
No. OncoTherapy Science does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade OncoTherapy Science from India?
The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.
Is there estate or inheritance tax on OncoTherapy Science shares held from India?
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.
Do I have to declare OncoTherapy Science shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your OncoTherapy Science holding, its cost and its closing value.
How do I sell OncoTherapy Science and bring the money back to India?
You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.